Arielle Elkrief1, Suzanne Kazandjian2, Thierry Alcindor1,2. 1. Cedars Cancer Center, McGill University Health Centre, Montreal, QC H4A 3J1, Canada. 2. Department of Medicine, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Abstract
BACKGROUND: Myxofibrosarcoma is a type of soft-tissue sarcoma that is associated with high rates of local recurrence and distant metastases. The first-line treatment for metastatic soft-tissue sarcoma has conventionally been doxorubicin-based. Recent evidence suggests that myxofibrosarcoma may be molecularly similar to undifferentiated pleomorphic sarcoma (UPS), which is particularly sensitive to gemcitabine-based therapy. The goal of this study was to evaluate the activity of gemcitabine-containing regimens for the treatment of metastatic myxofibrosarcoma refractory to doxorubicin. MATERIAL AND METHODS: We retrospectively evaluated seven consecutive cases of metastatic myxofibrosarcoma at our institution treated with gemcitabine-based therapy in the second-line setting, after progression on doxorubicin. Baseline clinical and baseline characteristics were collected. Primary endpoints were objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). RESULTS: After progression on first-line doxorubicin, a partial, or complete radiological response was observed in four of seven patients who received gemcitabine-based chemotherapy. With a median follow-up of 14 months, median progression-free and overall survival were 8.5 months and 11.4 months, respectively. CONCLUSIONS: Gemcitabine-based chemotherapy was associated with encouraging response rates in this cohort, similar to those seen in UPS. Both entities could be studied together for novel gemcitabine-based regimens.
BACKGROUND: Myxofibrosarcoma is a type of soft-tissue sarcoma that is associated with high rates of local recurrence and distant metastases. The first-line treatment for metastatic soft-tissue sarcoma has conventionally been doxorubicin-based. Recent evidence suggests that myxofibrosarcoma may be molecularly similar to undifferentiated pleomorphic sarcoma (UPS), which is particularly sensitive to gemcitabine-based therapy. The goal of this study was to evaluate the activity of gemcitabine-containing regimens for the treatment of metastatic myxofibrosarcoma refractory to doxorubicin. MATERIAL AND METHODS: We retrospectively evaluated seven consecutive cases of metastatic myxofibrosarcoma at our institution treated with gemcitabine-based therapy in the second-line setting, after progression on doxorubicin. Baseline clinical and baseline characteristics were collected. Primary endpoints were objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). RESULTS: After progression on first-line doxorubicin, a partial, or complete radiological response was observed in four of seven patients who received gemcitabine-based chemotherapy. With a median follow-up of 14 months, median progression-free and overall survival were 8.5 months and 11.4 months, respectively. CONCLUSIONS:Gemcitabine-based chemotherapy was associated with encouraging response rates in this cohort, similar to those seen in UPS. Both entities could be studied together for novel gemcitabine-based regimens.
Authors: George Z Li; Tomoyo Okada; Young-Mi Kim; Narasimhan P Agaram; Francisco Sanchez-Vega; Yawei Shen; Norifumi Tsubokawa; Jordan Rios; Axel S Martin; Mark A Dickson; Li-Xuan Qin; Nicholas D Socci; Samuel Singer Journal: Cancer Res Date: 2020-03-11 Impact factor: 12.701
Authors: Ian Judson; Jaap Verweij; Hans Gelderblom; Jörg T Hartmann; Patrick Schöffski; Jean-Yves Blay; J Martijn Kerst; Josef Sufliarsky; Jeremy Whelan; Peter Hohenberger; Anders Krarup-Hansen; Thierry Alcindor; Sandrine Marreaud; Saskia Litière; Catherine Hermans; Cyril Fisher; Pancras C W Hogendoorn; A Paolo dei Tos; Winette T A van der Graaf Journal: Lancet Oncol Date: 2014-03-05 Impact factor: 41.316
Authors: Andrea Sambri; Massimiliano De Paolis; Paolo Spinnato; Davide Maria Donati; Giuseppe Bianchi Journal: Oncol Res Treat Date: 2020-05-25 Impact factor: 2.825
Authors: Hussein A Tawbi; Melissa Burgess; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; James Hu; Sandra D'Angelo; Steven Attia; Richard F Riedel; Dennis A Priebat; Sujana Movva; Lara E Davis; Scott H Okuno; Damon R Reed; John Crowley; Lisa H Butterfield; Ruth Salazar; Jaime Rodriguez-Canales; Alexander J Lazar; Ignacio I Wistuba; Laurence H Baker; Robert G Maki; Denise Reinke; Shreyaskumar Patel Journal: Lancet Oncol Date: 2017-10-04 Impact factor: 41.316
Authors: R Hill; M Rabb; P A Madureira; D Clements; S A Gujar; D M Waisman; C A Giacomantonio; P W K Lee Journal: Cell Death Dis Date: 2013-09-05 Impact factor: 8.469
Authors: Haa-Na Song; Min Gyu Kang; Jeong Rang Park; Jin-Yong Hwang; Jung Hun Kang; Won Seop Lee; Gyeong-Won Lee Journal: Cancer Res Treat Date: 2018-01-22 Impact factor: 4.679
Authors: Anthony P Conley; Wei-Lien Wang; John A Livingston; Vinod Ravi; Jen-Wei Tsai; Ali Ali; Davis R Ingram; Caitlin D Lowery; Christina L Roland; Neeta Somaiah; Patrick Hwu; Cassian Yee; Vivek Subbiah; Andrew Futreal; Alexander J Lazar; Shreyaskumar Patel; Jason Roszik Journal: Cancers (Basel) Date: 2019-05-15 Impact factor: 6.639
Authors: Vittoria Colia; Marco Fiore; Salvatore Provenzano; Elena Fumagalli; Rossella Bertulli; Carlo Morosi; Angelo P Dei Tos; Marta Barisella; Alessandro Gronchi; Paolo G Casali; Roberta Sanfilippo Journal: Clin Sarcoma Res Date: 2017-08-22
Authors: Maria Chara Stylianidi; Lena Haeberle; Matthias Schott; Yuriko Mori; Christina Antke; Frederick Lars Giesel; Gerald Antoch; Irene Esposito; Wolfram Trudo Knoefel; Andreas Krieg Journal: Surg Case Rep Date: 2022-07-25